Nordic Nanovector ASA (OSE: NANO), a company committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care, has reported its financial results for 2019, on Thursday.
Revenues for the full year 2019 were NOK0.0m, the same as last year.
The company reported total operating expenses for 2019 at NOK440.4m compared to NOK340m in 2018.
The firm posted comprehensive loss for 2019 at NOK433.3m compared to NOK336.8m in 2018.
Jan H Egberts, MD, chairman of Nordic Nanovector, commented: 'We currently have 47 patients enrolled in our pivotal PARADIGME Phase 2b trial evaluating Betalutin. The company will under its new management look into the current strategy and operational trial initiatives. We still aim to complete the patient enrolment in PARADIGME in the second half of 2020. The encouraging efficacy and safety profile demonstrated in the first part of the LYMRIT 37-01 Phase 1/2 trial with a single administration of Betalutin give the Board and management confidence in its potential to become an important option for patients with non-Hodgkin's lymphoma (NHL).'
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
Neurizon enters global license agreement with Elanco to commercialise NUZ-001
Ascletis doses first US participants in ASC30 Phase IIa study for obesity treatment
Jacobio's JAB-8263 Phase I/II Clinical Trial IND application receives Chinese regulatory approval